Victor Rusu
Principal at Apple Tree Partners
Greater Boston
Overview
Work Experience
Principal
2019 - Current
Apple Tree Partners is a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services.
Raised $5,000,000.00.
Senior Biotechnology Associate at Citi
2018 - 2019
Citigroup is a financial services holding company that provides various financial products and services.
Raised $12,950,000,000.00 from ValueAct Capital and Abu Dhabi Investment Authority.
Senior Scientist
2017 - 2018
Jnana Therapeutics develops innovative therapies using a chemoproteomics drug discovery platform.
Raised $207,000,000.00 from AbbVie, Avalon Ventures, Bain Capital Life Sciences, RA Capital Management, Polaris Partners, Pfizer Venture Investments and Versant Ventures.
PhD Graduate Student
2012 - 2017
- Identified molecular mechanisms through which mutations in a previously uncharacterized gene, SLC16A11, increase type 2 diabetes (T2D) risk. These mutations are among the largest known T2D risk factors. - Characterized function of SLC16A11 and impact of T2D-associated mutations using unbiased methods: metabolomics, RNA-sequencing, proteomics, and ChIP-sequencing. - Used targeted biochemical assays to demonstrate the impact of T2D-associated coding mutations on SLC16A11 binding to a chaperone protein and the resulting effects on cellular localization. - Used gene expression studies, allelic imbalance assays, and reporters to investigate impact of T2D-associated noncoding mutations on SLC16A11 gene regulation. - Performed functional experiments in primary human hepatocytes investing role of SLC16A11 in metabolism.